CA
NZ
UK
AU
IND
US
Organic revenue grew about 12%, or roughly $469 million, while acquisitions contributed $716 million.Net Incomewas $167.7 million, compared with $166.5 million, but net income attributable to MasTec fell to $150.6 million from $160.7 million, partly because non-controlling interests took $17.2 million versus $5.8 million. …
Net income attributable to stockholders was $2.4 million, or $0.10 per diluted share, down from $7.8 million, or $0.32, in the third quarter of 2025. Income before taxes was $7.1 million, compared with $19.5 million a year earlier.
Therapeutic sales rose 14.0% to $140.5 million from $123.3 million. Endoscopy grew 32.9% to $23.4 million, Therapeutic OEM rose 31.5% to $13.1 million, Oncology rose 16.4% to $27.1 million, and Cardiac Therapies rose 7.9% to $27.5 million. Renal Therapies slipped 1.9% to $13.6 million.
Net revenue, defined as revenues less cost of revenues, grew 20%, or $21.5 million, to $131.0 million from $109.5 million. The company tied the increase mainly to theOptionsbusiness, citing higher industry volumes and higher non-transaction revenue. Chairman and CEO Thomas P. Gallagher called the …
Middlesex system revenues rose $4.7 million on higher wholesale demand, customer consumption andBase Rateincreases effective February 23, 2026. Tidewater revenues rose $1.2 million on higher consumption, customer growth and rate increases, and non-regulated revenues rose $0.2 million.
Cost of goods sold grew 8% to $425.7 million. Production margin fell 6% to $129.2 million from $137.0 million, or 23.3% of sales on a calculated basis versus 25.7%.
Volumes declined approximately 4% on an adjusted basis, which management tied mainly to soft market demand. Price and mix contributed approximately 4% to sales growth, helped by price increases taken in response to risingInflationalong with positive mix.
Reported operating income jumped $1,014 million to $1,758 million. The company's reconciliation shows mark-to-market gains fromDerivativesof $543 million this year, compared with losses of $348 million in the prior year quarter, a swing of $891 million.
Revenue was $1,202.4 million, up 22.6% from $980.6 million in the second quarter and 63.1% from $737.2 million in the third quarter of 2025. CEO Michael Hsing said the company sees accelerated growth.
Net income was $0.4 million, or $0.03 per diluted share, compared with $12.3 million, or $0.93, in the second quarter and $17.1 million, or $1.32, a year earlier.
Please wait processing your request...